- Home
- CIGL vs RLMD Comparison
CIGL vs RLMD Comparison
Compare CIGL & RLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CIGL
- RLMD
- Stock Information
- Founded
- CIGL 1997
- RLMD 2004
- Country
- CIGL Singapore
- RLMD United States
- Employees
- CIGL N/A
- RLMD N/A
- Industry
- CIGL Diversified Commercial Services
- RLMD Biotechnology: Pharmaceutical Preparations
- Sector
- CIGL Consumer Discretionary
- RLMD Health Care
- Exchange
- CIGL Nasdaq
- RLMD Nasdaq
- Market Cap
- CIGL 46.7M
- RLMD 52.8M
- IPO Year
- CIGL 2025
- RLMD N/A
- Fundamental
- Price
- CIGL $3.46
- RLMD $1.59
- Analyst Decision
- CIGL
- RLMD Buy
- Analyst Count
- CIGL 0
- RLMD 3
- Target Price
- CIGL N/A
- RLMD $5.00
- AVG Volume (30 Days)
- CIGL 7.9M
- RLMD 1.6M
- Earning Date
- CIGL 01-01-0001
- RLMD 11-06-2025
- Dividend Yield
- CIGL N/A
- RLMD N/A
- EPS Growth
- CIGL N/A
- RLMD N/A
- EPS
- CIGL N/A
- RLMD N/A
- Revenue
- CIGL $10,490,668.00
- RLMD N/A
- Revenue This Year
- CIGL N/A
- RLMD N/A
- Revenue Next Year
- CIGL N/A
- RLMD N/A
- P/E Ratio
- CIGL N/A
- RLMD N/A
- Revenue Growth
- CIGL N/A
- RLMD N/A
- 52 Week Low
- CIGL $1.40
- RLMD $0.24
- 52 Week High
- CIGL $31.06
- RLMD $3.98
- Technical
- Relative Strength Index (RSI)
- CIGL N/A
- RLMD 74.57
- Support Level
- CIGL N/A
- RLMD $1.44
- Resistance Level
- CIGL N/A
- RLMD $1.72
- Average True Range (ATR)
- CIGL 0.00
- RLMD 0.24
- MACD
- CIGL 0.00
- RLMD 0.05
- Stochastic Oscillator
- CIGL 0.00
- RLMD 86.90
About CIGL Concorde International Group Ltd Class A Ordinary Shares
Concorde International Group Ltd is an integrated security services provider that combines physical manpower and technology to deliver effective security solutions. The company offers a range of services to enhance security and safety: (1) i-Guarding Services; (2) Man-Guarding Services; and (3) Consultancy and Training Services. Its i-Guarding Services leverages technology to increase efficiency, with a mobile platform and cluster aggregation model of a higher skillset workforce. It has two operating segments, which are (i) security services; and (ii) training school. Key revenue is generated from Security Services.
About RLMD Relmada Therapeutics Inc.
Relmada Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing chemical entities with novel versions of drug products that address areas of high unmet medical need in the treatment of central nervous system diseases. The company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Its key product candidate, esmethadone, is an oral agent for the treatment of depression and other potential indications.